Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma

Stefanie S. Schalm,1* Erin O’Hearn,1 Kevin Wilson,1 Timothy P. LaBranche,1 Grace Silva,1 Zhuo Zhang,1 Lucian DiPietro,1 Neil Bifulco,1 Richard Woessner,1 Nicolas Stransky,1 Darshan Sappal,1 Robert Campbell,1 Riadh Lobbardi,1 Michael Palmer,1 Joseph Kim,1 Chaoyang Ye,1 Marion Dorsch,1 Christoph Lengauer,1 Timothy Guzi,1 Vivek Kadambi,1 Andrew Garner,1 Klaus P. Hoeflich1

1Blueprint Medicines Corporation, Cambridge, Massachusetts

Authors’ contributions: The project was originally conceived and designed by S.S., K.W., N.S., C.L., and K.H. Acquisition and analyses of data were done by S.S., E.O., K.W., T.L., G.S., Z.Z., L.D., N.B., R.W., D.S., R.C., R.L., and C.Y. All authors were involved in data interpretation. The manuscript was edited and revised by S.S. All the authors have read and approved of the final manuscript.

Short title: PRKACA as a therapeutic target in FLC

*Correspondence to:

Stefanie S. Schalm
Address: 45 Sidney Street, Cambridge, Massachusetts 02139
Phone: 617-2726476
Email: stefanie.schalm@gmail.com
Word count of main document text: 3456/7000 (excluding methods, references and figure legends)

DOI: https://doi.org/10.1101/2022.01.31.477690
Abbreviations

ATP, adenosine-5'-triphosphate

cAMP, 3' 5'-cyclic adenosine monophosphate

CCC, cholangiocellular carcinoma

cDNA, complementary DNA

CDX, cell line derived xenograft

CPS1, carbamoyl phosphate synthetase 1

CREB, cAMP-responsive binding protein

DMEM, Dulbecco’s Modified Eagle Medium

DMSO, dimethyl sulfoxide

DNAJB1, heat shock protein 40

EDTA, ethylenediaminetetraacetic acid

ESRRA, estrogen related receptor alpha

FLC, fibrolamellar carcinoma

G6PC, glucose-6-phosphatase catalytic subunit

HNF4a, hepatocyte nuclear factor 4 alpha

HCC, hepatocellular carcinoma

IC50, half-maximal inhibitory concentration

Kd, dissociation constant

NT, non-targeting

PDX, patient-derived xenograft

PKA, protein kinase A

PRKACA, protein kinase cAMP-activated catalytic subunit alpha

PYGL, glycogen phosphorylase, liver form

QD, once daily
SHH, sonic hedgehog

shRNA, short hairpin ribonucleic acid

VASP, vasodilator-stimulated phosphoprotein

WT, wild type
Acknowledgements

Medical writing support was provided by Allison Cherry, PhD, and Elizabeth G. Wheatley, PhD, of Nexus Global Group Science, LLC, and editorial support, including formatting, proofreading, and submission was provided by Travis Taylor, BA, Paragon, Knutsford, supported by Blueprint Medicines Corporation according to Good Publication Practice guidelines (www.ismpp.org/gpp3). Lola Reid, PhD, of University of North Carolina at Chapel Hill, was involved in data generation at the start of the project. The Sponsor was involved in the study design, collection, analysis and interpretation of data, as well as data checking of information provided in the manuscript. However, ultimate responsibility for opinions, conclusions, and data interpretation lies with the authors.

Conflicts of Interest

These authors disclose the following: Stefanie S. Schalm is a current or former employee and shareholder of Blueprint Medicines Corporation and Kymera Therapeutics; has a patent in conjunction with Blueprint Medicines Corporation. Erin O’Hearn is a current or former employee of Blueprint Medicines Corporation and Scorpion Therapeutics. Kevin Wilson is a current or former employee and shareholder of Blueprint Medicines Corporation, Foghorn Therapeutics, and Merck & Co. Timothy LaBranche is a current employee, leadership role and shareholder of Blueprint Medicines Corporation. Grace Silva is a current or former employee of Blueprint Medicines Corporation and Tessara Therapeutics; shareholder of Blueprint Medicines Corporation, Constellation Pharmaceuticals Inc., CytomX Therapeutics, Inc., Fulcrum Therapeutics Inc., Jounce Therapeutics Inc., and Kala Pharmaceuticals, Inc; received research funding from Blueprint Medicines...
Corporation. Zhuo Zhang is a current employee and shareholder of Blueprint Medicines Corporation. Lucian DiPietro and Neil Bifulco have patents in conjunction with Blueprint Medicines Corporation. Richard Woessner is a current or former employee of Onkur Therapeutics and Blueprint Medicines Corporation; shareholder of AstraZeneca and Blueprint Medicines Corporation; has patent in conjunction with AstraZeneca. Nicolas Stransky is a current employee of Celsius Therapeutics; shareholder of Blueprint Medicines Corporation and Celsius Therapeutics; and has patents in conjunction with Blueprint Medicines Corporation. Darshan Sappal is a current employee of Foghorn Therapeutics and shareholder of Blueprint Medicines Corporation. Robert Campbell is a current employee and shareholder of Blueprint Medicines Corporation. Riadh Lobbaridi is a former employee of Blueprint Medicines Corporation and a current employee of C4 Therapeutics; shareholder of Blueprint Medicines Corporation, C4 Therapeutics, Eyepoint Pharmaceuticals, Inc., Jounce Therapeutics, Magenta Therapeutics, Inc., Moleculin Biotech, Inc., Neon Therapeutics, and Surface Oncology, Inc. Michael Palmer is a current or former employee of Blueprint Medicines Corporation and C4 Therapeutics; shareholder of C4 Therapeutics, Magenta Therapeutics, and Sesen Bio; has a patent in conjunction with Blueprint Medicines Corporation. Joseph L. Kim is a current employee and shareholder of Blueprint Medicines Corporation; has a patent in conjunction with Blueprint Medicines Corporation. Chaoyang Ye is a current or former employee of Blueprint Medicines Corporation and NewCo Pharma Ltd; shareholder of Blueprint Medicines Corporation. Marion Dorsch is a current or former employee of Blueprint Medicines Corporation and NewCo Pharma Ltd; has leadership position in Blueprint Medicines Corporation; shareholder of Blueprint medicines Corporation. Christoph Lengauer is a current employee and shareholder of Blueprint Medicines Corporation.
and Third Rock Ventures; has leadership roles with Blueprint Medicines Corporation, Celsius Therapeutics, EQRx, Hookipa Pharma, Mersana Therapeutics, Inc., MOMA Therapeutics, Third Rock Ventures, and Exact Sciences; shareholder of Blueprint Medicines Corporation, Celsius Therapeutics, EQRx, Hookipa Pharma, Mersana Therapeutics, Inc., MOMA Therapeutics, Relay Therapeutics, Third Rock Ventures, and Exact Sciences; received honoraria from and had consulting or advisory roles with Bayer, Blueprint Medicines Corporation, Celsius Therapeutics, EQRx, Hookipa Pharma, Mersana Therapeutics, Inc., MOMA Therapeutics, Relay Therapeutics, Third Rock Ventures, Thrive Earlier Detection, and Exact Sciences; received expenses from Blueprint Medicines Corporation, Celsius Therapeutics, EQRx, Hookipa Pharma, Mersana Therapeutics, Inc., MOMA Therapeutics, Relay Therapeutics, Third Rock Ventures, and Thrive Earlier Detection, and Exact Sciences; has patents in conjunction with Blueprint Medicines Corporation, Celsius Therapeutics, Johns Hopkins University, and Thrive Earlier Detection. Timothy Guzi is a current or former employee of Blueprint Medicines Corporation and MOMA Therapeutics; shareholder of Blueprint Medicines Corporation; has patents in conjunction with Blueprint Medicines Corporation. Vivek J. Kadambi is a current or former employee and shareholder of Blueprint Medicines Corporation and Vertex Pharmaceuticals. Andrew Garner is a current or former employee of Blueprint Medicines Corporation and MOMA Therapeutics; shareholder of Blueprint Medicines Corporation. Klaus P. Hoeflich is a current or former employee and shareholder of Blueprint Medicines Corporation and Nested Therapeutics; and holds an advisory role with Turbine AI.
Funding

This study was funded by Blueprint Medicines Corporation. Medical writing support was provided by Allison Cherry, PhD, and Elizabeth G. Wheatley, PhD, of Nexus Global Group Science, LLC and funded by Blueprint Medicines.

Data Transparency Statement

All data generated or analyzed during this study are included in this published article (and its supplementary information files) or available from the corresponding author on reasonable request.

Ethical Statement

The corresponding author, on behalf of all authors, jointly and severally, certifies that their institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and humane principles of research.
Abstract

**Background & Aims:** Fibrolamellar carcinoma (FLC) is a rare, difficult-to-treat liver cancer primarily affecting pediatric and adolescent patients, and for which precision medicine approaches have historically not been possible. The *DNAJB1-PRKACA* gene fusion was identified as a driver of FLC pathogenesis. We aimed to assess whether FLC tumors maintain dependency on this gene fusion and determine if PRKACA is a viable therapeutic target.

**Methods:** FLC patient-derived xenograft (PDX) shRNA cell lines were implanted subcutaneously into female NOD-SCID mice and tumors were allowed to develop prior to randomization to doxycycline (to induce knockdown) or control groups. Tumor development was assessed every 2 days. To assess the effect of treatment with novel selective PRKACA small molecule kinase inhibitors, BLU0588 and BLU2864, FLC PDX tumor cells were implanted subcutaneously into NOD-SCID mice and tumors allowed to develop. Mice were randomized to treatment (BLU0588 and BLU2864, orally, once daily) or control groups and tumor size determined as above.

**Results:** Knockdown of *DNAJB1-PRKACA* reversed a FLC-specific gene signature and reduced PDX tumor growth in mice compared to the control group. Furthermore, FLC PDX tumor growth was significantly reduced with BLU0588 and BLU2864 treatment versus control (*P* = 0.003 and *P* = 0.0005, respectively).

**Conclusions:** We demonstrated, using an inducible knockdown and small molecule approaches, that FLC PDX tumors were dependent upon *DNAJB1-PRKACA* fusion activity. In addition, this study serves as a proof-of-concept that PRKACA is a viable therapeutic target for FLC and warrants further investigation.
**Key words:** fibrolamellar carcinoma; PRKACA; DNAJB1-PRKACA; kinase inhibitor
Introduction

Fibrolamellar carcinoma (FLC) represents <1% of all liver cancers in the United States. FLC primarily affects pediatric or adolescent patients, with the majority of patients being under 40 years old. Surgery is the mainstay treatment for FLC; there has been no clear benefit demonstrated with any chemotherapy or multi-kinase inhibitors, including sorafenib, which is the standard treatment for hepatocellular carcinoma (HCC). FLC is often not diagnosed until the disease has metastasized, which complicates surgical resection. Most patients experience disease recurrence within 5 years, and the 5-year survival rate is approximately 75%-85% for resected patients. New therapies are needed; however, until recently, precision medicine approaches have not been possible due to a lack of an identified driver of FLC pathogenesis.

FLC is clinically, histologically, and molecularly distinct from the most common forms of liver cancer, including HCC and cholangiocellular carcinoma (CCC). FLC is identified histologically by large tumor cells arranged in a cord-like network surrounded by lamellated collagen fibers, and is not typically associated with elevated α-fetoprotein. FLC can be characterized by positive immunohistochemical staining for markers of both hepatocyte and biliary differentiation including cytokeratin 7 and CD68, yet is often negative for the HCC marker glypican 3. An FLC-specific gene expression signature has been identified that can further distinguish it from healthy liver, HCC, and CCC.

In 2014, an analysis of 15 FLC tumor samples yielded the discovery of an aberrant fusion between protein kinase A (PKA) alpha catalytic subunit (PRKACA) and heat shock protein 40 (DNAJB1) genes that was hypothesized to be a critical
molecular event in FLC pathogenesis. The DNAJB1-PRKACA fusion is not expressed by normal surrounding liver tissue or other liver cancer types, but has been identified in 79%–100% of FLC tumor samples and is functionally capable of driving FLC tumorigenesis when expressed in mice, making its presence a distinguishing hallmark of FLC and a likely driver of FLC tumorigenesis.

The 3′ 5′-cyclic adenosine monophosphate (cAMP)-regulated PKA tetramer is comprised of 2 catalytic subunits and 2 regulatory subunits. In the presence of cAMP, the catalytic subunits disassociate from regulatory subunits and become active. PKA regulates a broad array of cellular functions throughout the body. Through its regulation of transcriptional elements, the PKA signaling pathway is involved in liver metabolism. The chimeric kinase resulting from the DNAJB1-PRKACA fusion retains the kinase activity of PRKACA. The DNAJB1-PRKACA fusion protein is expressed at a higher level than wild-type (WT) PRKACA, and it has been postulated that these higher levels lead to increased cAMP-independent PKA signaling. The molecular mechanism of how the DNAJB1-PRKACA fusion contributes to FLC pathogenesis remains incompletely understood, and it is still not fully clear whether FLC tumors maintain dependency on DNAJB1-PRKACA expression for their continued growth, and whether PRKACA is a viable therapeutic target.

In this study, we demonstrate that 2 different modes of PRKACA inhibition result in FLC tumor growth inhibition and reversal of an FLC gene expression signature, using a patient-derived xenograft (PDX) FLC mouse model. This study serves as a proof-of-concept for PRKACA as a viable target for FLC.
Results

*Characterization of FLC Patient-Derived Xenograft Mouse Model*

The FLC PDX tumor model LI5132 expressed high levels of DNAJB1-PRKACA fusion protein and, to a lesser extent, the smaller WT PRKACA protein, distinguishable by their size difference via gel electrophoresis ([Figure 1a](#)). By contrast, Hep3B cell line-derived xenograft tumors expressed only WT PRKACA protein ([Figure 1a](#)). The high expression of PRKACA in FLC PDX tumor tissue is likely due to the replacement of exon 1 of *PRKACA* with exon 1 of *DNAJB1* containing the more active *DNAJB1* promoter and upregulating PRKACA protein expression ([Supplementary Figure S1a, S1b](#)). Phosphorylation of the PRKACA downstream targets, cAMP-responsive binding protein (CREB) and vasodilator-stimulated phosphoprotein (VASP), were measured to assess the cellular activity of DNAJB1-PRKACA fusion protein. Both CREB (Ser133) and VASP (Ser157) phosphorylation was increased in FLC PDX tumor tissue compared with Hep3B cell line derived xenograft (CDX) tumor tissue, supporting enhanced activation of PRKACA signaling from DNAJB1-PRKACA fusion expression ([Figure 1a](#)). Importantly, PDX tumors recapitulated the fibrolamellar histology that is observed in FLC, characterized by large cells with abundant cytoplasm, positive expression of cytokeratin 7 and CD68, and negative expression of glypican 3 ([Figure 1b](#)).

*Cellular Effects of the DNAJB1-PRKACA Fusion Protein in FLC PDX Spheroid Cultures*

Western blot analysis of in vitro cultured engineered cell lines ([Figure 2a](#)) confirmed that doxycycline induction of the 3 PRKACA short hairpin ribonucleic acid
(shRNA) constructs, but not the non-targeting (NT) shRNA construct, led to a reduction in both DNAJB1-PRKACA and WT PRKACA protein (Figure 2b). Doxycycline induction of the PRKACA shRNAs, but not the NT shRNA, also strongly reduced VASP phosphorylation, indicative of reduced PRKACA downstream signaling (Figure 2b). Cell proliferation was not appreciably different in PRKACA shRNA cell lines before and after induction (Figure 2c). Treatment with forskolin did not further enhance CREB and VASP phosphorylation in the FLC PDX tumor extracts (Figure 2d), suggesting PRKACA signaling is already fully activated by DNAJB1-PRKACA. By contrast, forskolin produced a strong effect on PRKACA signaling in Huh7 HCC cell extracts, which have a low basal level of unstimulated PRKACA activity (Figure 2d).

**Knockdown of DNAJB1-PRKACA Fusion Protein Inhibits Tumor Growth In Vivo**

In mice harboring 1 of the 3 different PRKACA shRNA-expressing cell line xenografts (shRNAs #1, #2, and #4) treated with doxycycline, tumor growth was reduced over time compared with mice that were untreated (Figure 3a-3c). Importantly, tumor growth was unaffected by doxycycline treatment in mice harboring xenografts with NT shRNA (Figure 3d). Western blot analysis of tumor tissue from mice implanted with the shRNA #1 cell line indicated that expression of DNAJB1-PRKACA fusion protein, but not WT PRKACA, was reduced at 10 and 20 days of doxycycline treatment (Figure 3e), consistent with the observed reduction in tumor growth (Figure 3a). Induction of NT shRNA did not affect the expression levels of DNAJB1-PRKACA or WT PRKACA (Figure 3e). WT PRKACA expression appeared stable in the presence of doxycycline in the shRNA #1 cell line (Figure 3e),
potentially due to endogenous expression of PRKACA from non-transfected mouse stromal cells.

Western blot analysis of shRNA #2 tumors indicated DNAJB1-PRKACA expression was also reduced 10 days after doxycycline treatment but recovered over time, with DNAJB1-PRKACA expression reaching baseline levels by approximately 28 days after doxycycline treatment (Figure 3f). Similar to the DNAJB1-PRKACA fusion expression levels, a slight recovery in the growth rate of xenograft tumors in mice treated with doxycycline is evident over time and could be due to the recovery of DNAJB1-PRKACA fusion protein levels via outgrowth of clonal populations with weaker DNAJB1-PRKACA knockdown (Figure 3b). In further support of the growth-suppressive role of DNAJB1-PRKACA knockdown, the percentage of cells positive for the cellular proliferation marker Ki67 was reduced 10 days after doxycycline treatment in PDX tumors expressing PRKACA shRNA #2 (Figure 3g and 3h). In line with DNAJB1-PRKACA fusion protein expression recovering approximately 28 days following doxycycline treatment, Ki67 expression also recovered to near-baseline levels by 28 days post-induction (Figure 3g, 3h).

The PRKACA-Selective Inhibitors BLU0588 and BLU2864 Inhibit PRKACA Signaling In Vitro and Reduce FLC Tumor Growth In Vivo

A library of over 10,000 chemically diverse kinase inhibitors annotated against the human kinome was interrogated to identify compounds with inhibitory activity against PRKACA. Iterative medicinal chemistry optimization was performed from these initial compounds to improve PRKACA potency, selectivity against related AGC-family kinases, and pharmaceutical properties, leading to the generation of 2 structurally distinct inhibitors, BLU0588 and BLU2864 (Figure 4a). Kinome-wide
selectivity was assessed by testing BLU0588 and BLU2864 at 3 μM concentration across a panel of 400 human kinases using the KINOMEScan® methodology. This profiling revealed that BLU0588 and BLU2864 have good to moderate selectivity against closely related AGC kinase family members, and excellent overall kinome selectivity profiles, with [S(10)] selectivity scores of 0.047 and 0.057, respectively (Supplementary Table S1). As follow up, the dissociation constant (Kd) was determined for all non-mutant kinases that were bound by either BLU0588 or BLU2864 with >90% occupancy at the 3-μM screening concentration. Measurement of the Kd demonstrated that both molecules had the most potent binding affinity to PRKACA, 4 nM, and 3.3 nM, respectively. BLU0588 and BLU2864 exhibited a Kd value <100 nM for only 9 or 10 of the non-mutant kinases identified in the kinome screening assay (Supplementary Table S2).

BLU0588 and BLU2864 inhibited PRKACA catalytic activity with a half-maximal inhibitory concentration (IC50) of 1 nM and 0.3 nM, respectively, compared to an IC50 of 83.1 nM (83-fold) and 12.7 nM (42-fold) for the closely related AGC kinase ROCK2 (Supplementary Table S1). For BLU0588, AKT1, AKT2, and AKT3 (AGC kinases that are also closely related to PRKACA), IC50 values were 1540 nM, 3780 nM, and 397 nM, respectively; corresponding values for BLU2864 were 2120 nM, 4910 nM, and 475 nM (Supplementary Table S1). PRKACA cellular IC50 values were 25.0 nM and 36.6 nM with BLU0588 and BLU2864, respectively, which were determined from inhibition of VASP Ser157 phosphorylation in forskolin-stimulated Huh7 cells (Supplementary Table S1; Figure 4b). These results show BLU0588 and BLU2864 exhibited a strong degree of selectivity for PRKACA.
BLU0588 treatment led to a dose-dependent reduction in phosphorylated VASP in FLC PDX spheroid cultures, indicative of inhibited PRKACA signaling in the disease model (Figure 4b and Supplementary Figure S2). Similar to the effect of DNAJB1-PRKACA knockdown, proliferation was not substantially inhibited in by BLU0588 treatment in the FLC PDX spheroid model (Figure 4c). Further, in a second FLC-PDX model using Tu-2010 human spheroid cultures characterized by Oikawa et al., a dose-dependent reduction in phosphorylated VASP was also observed following BLU9058 treatment, another selective PRKACA inhibitor structurally similar to BLU0588 (Supplementary Figure S3).

For in vivo studies, mice were given either BLU0588 at 30 mg/kg and 75 mg/kg once daily (QD) or BLU2864 at 30 mg/kg and 45 mg/kg QD and monitored for 24 hours. Plasma concentrations peaked within 2–4 hours of QD dosing (Figure 4d). For BLU0588-treated mice, phosphorylated VASP was reduced to 19% and 4% of baseline phosphorylation levels with 30 mg/kg QD and 75 mg/kg QD, respectively, 4 hours after dosing; phosphorylated VASP levels fully recovered by 24 hours post-administration of 30 mg/kg QD. BLU2684 at 30 mg/kg QD reduced phosphorylated VASP levels to 27% of baseline 2 hours after dosing, which recovered by 24 hours post-administration of BLU2864 30 mg/kg and 45 mg/kg QD. These data indicate a single oral dose of BLU0588 and BLU2864 can inhibit PRKACA in vivo (Figure 4d). In a 28-day rat tolerability study dose levels up to 15 mg/kg/day were well tolerated with no clinical signs noted. Animals in the top dose group (30 mg/kg) however showed reduced activity after a few days, followed by death after 6-7 days. The cause of death in these animals was not identified. The highest tolerated dose of BLU0588 and of BLU2864 for more than 3 weeks of continuous dosing was established as 30 mg/kg QD in mice (Figure 4e). When mice harboring FLC PDX
tumors were treated with BLU0588 or BLU2864 both given orally at 30 mg/kg QD, by Day 34 tumor growth was inhibited by 48.5% \( (P = 0.003) \) and by 45.3% \( (P = 0.0005) \), respectively (Figure 4f). These data suggest FLC PDX tumor growth is dependent on PRKACA catalytic activity.

**BLU0588 and PRKACA shRNA Define a Gene Signature of PRKACA Inhibition in FLC**

To determine an FLC gene signature that depends on PRKACA expression, we performed RNA sequencing of 3 FLC PDX cell lines expressing PRKACA shRNA (shRNA #1, #2, and #3) and the NT shRNA control. Less than approximately 1% of the total reads per sample aligned to the mouse genome (GENCODE GRCm38/mm10), confirming that purification of human tumor cells was successful. The small number of aligned mouse reads were removed prior to expression quantification using Salmon\(^{31}\). The majority (81\%–97\%) of PRKACA reads per sample were identified as the \textit{DNAJB1-PRKACA} fusion and were not \textit{PRKACA} WT (Supplementary Table S3), further supporting that the \textit{DNAJB1-PRKACA} fusion is overexpressed and driving the FLC phenotype (Supplementary Figure S1b). A significant reduction in PRKACA transcript level (Wilcoxon Signed Rank test \( P = 0.022 \)) was observed with shRNA knockdown (Supplementary Figure S4). We detected 572 protein-coding genes that are differentially expressed in all 3 PRKACA shRNA PDX cell lines vs the NT control line (242 negative fold change, Supplementary Table S4a; 330 positive fold change, Supplementary Table S4b and Supplementary Figure S5). Of those, 90 genes are shared between our experiment and FLC tissue vs normal adjacent tissue as described in Simon et al\(^ {14}\) (Supplementary Figure S5 and Supplementary Tables S4a and S4b).
We detected 817 protein-coding genes that were differentially expressed in BLU0588 vs dimethyl sulfoxide (DMSO)-treated FLC PDX cells (323 negative fold change and 494 positive fold change; Supplementary Tables S4a and S4b, respectively). By matching the inverse log$_2$ fold change across the list of BLU0588-modulated genes and the list of FLC-related genes previously reported by Simon et al.\textsuperscript{14}, we identified a significant overlap between these 2 gene sets ($n = 175$; Fisher exact test $P = 0.0005$; Supplementary Tables S5a and S5b). Importantly, the list of BLU0588-modulated genes and the list of PRKACA shRNA-modulated genes showed a significant overlap of differentially expressed genes, defining a signature of PRKACA inhibition ($N = 206$; Fisher exact test $P < 2.2 \times 10^{-16}$), and suggests that the kinase activity of the DNAJB1-PRKACA fusion protein drives FLC-specific gene expression (Figure 5a; Supplementary Figures S6a and S6b). Next, we compared the list of genes affected by PRKACA inhibition identified above to the FLC gene signature identified by Simon et al.\textsuperscript{14} to determine those that can be reversed by PRKACA inhibition. By matching the inverse log$_2$-fold change across both gene lists, we identified a core set of 39 FLC genes that are modulated by both BLU0588 treatment and shRNA knockdown and have an inverse modulation in FLC (Figure 5b and Supplementary Figure S6b, Supplementary Tables S6a and S6b). These genes include FLC markers such as carbamoyl phosphate synthetase 1 (CPS1), KRT86, and sonic hedgehog (SHH).

To identify FLC pathways that are modulated in our signature of PRKACA inhibition and overlap with the Simon et al.\textsuperscript{14} gene set, we searched the canonical pathway collection available through the Molecular Signatures Database\textsuperscript{32, 33}. We observed enrichment of pathways associated with liver and hepatocyte functions, including detoxification (drug metabolism of cytochrome P450 and biological...
oxidations), metabolism (retinol metabolism) and synthesis (steroid hormonal biosynthesis) with PRKACA inhibition, suggesting a reversal in FLC-affected pathways.

Since PRKACA is known to directly phosphorylate and modulate transcription factors 34, we searched for enrichment of transcription factor binding motifs from genes modulated by BLU0588, PRKACA shRNA knockdown, and the combined signature of PRKACA inhibition. Using the Hypergeometric Optimization of Motif Enrichment 33 motif finding tool, we identified previously described as well as novel transcription factor binding motifs (Supplementary Figure S7a). Hepatocyte nuclear factor 4 alpha (HNF4a) and JUN motifs are modulated in FLC 35, HNF4a is critical for liver-specific gene expression 36, and PKA directly phosphorylates and inhibits HNF4a function 37. When using the Clarivate Metacore analysis, we discovered that transcription factor estrogen related receptor alpha (ESRRA) appears to be the central direct target downstream of PRKACA, through which many other affected genes and transcription factors are connected. This interaction has previously been documented 38, and ESRRA is known to be central in hepatic metabolic dysfunction and diseases 39 (Supplementary Figure S7b).

To validate that PRKACA knockdown by shRNA or inhibition by BLU0588 treatment can reverse FLC-specific gene alterations, 4 genes were selected that are transcriptionally altered in FLC based on our RNA sequencing data: 2 upregulated genes, CPS1 and glucose-6-phosphatase catalytic subunit (G6PC); and 2 downregulated genes, glycogen phosphorylase, liver form (PYGL) and SHH 14. In 3 PRKACA shRNA-expressing cell lines, quantitative polymerase chain reaction assessment showed that upon doxycycline induction, CPS1 and G6PC expression
decreased, while PYGL and SHH increased in the 3 cell lines tested (Figure 6a). Expression of G6PC and SHH was unaffected by doxycycline in cells expressing non-targeting shRNA; however, expression of CPS1 was moderately decreased and PYGL was moderately increased following doxycycline induction in cells expressing non-targeting shRNA. Similarly, in cells treated with BLU0588, expression of CPS1 and G6PC were dose-dependently downregulated by BLU0588 treatment; this effect was observed within 24 hours of treatment, likely due to direct regulation. Expression of PYGL and SHH were dose-dependently upregulated by BLU0588 treatment, but this effect was observed after 14 days, suggesting this regulation is more indirect (Figure 6b; and Supplementary Figs. S8a and S8b). The IC_{50} values of these effects were between 55 nM and 180 nM, further suggesting gene expression can be modulated by directly inhibiting PRKACA kinase activity with BLU0588 (Supplementary Figure S8).
Discussion/Conclusion

This study is the first to evaluate the therapeutic potential for PRKACA inhibition in FLC. We characterized and validated an FLC PDX mouse model \(^{27}\), and showed that PRKACA signaling and FLC-specific gene expression are dependent on DNAJB1-PRKACA fusion protein expression. Importantly, we demonstrated with 2 different modes of PRKACA inhibition that FLC PDX in vivo tumor growth was dependent on DNAJB1-PRKACA expression, supporting the notion that DNAJB1-PRKACA drives FLC tumor growth, and validating PRKACA as a therapeutic target for FLC. The selective PRKACA inhibitors developed in this study can also be used to validate PRKACA as a target for other diseases and to further study the molecular function of PRKACA.

We showed that DNAJB1-PRKACA fusion protein is overexpressed relative to WT PRKACA in an FLC PDX mouse model, consistent with reports of DNAJB1-PRKACA expression in FLC patient tumor samples \(^{15,25}\). Moreover, downstream signaling of PRKACA was increased in FLC PDX tumors relative to Hep3B xenograft tumors that lack the DNAJB1-PRKACA fusion protein. Using this validated model of FLC PDX tumors, we showed that decreasing DNAJB1-PRKACA fusion protein levels both reduced downstream activity of the PRKACA pathway and reversed an FLC-specific gene signature. In PDX tumors, induction of PRKACA knockdown with doxycycline significantly reduced tumor growth, and the timing of this decrease in growth rate corresponded to the timing of DNAJB1-PRKACA knockdown and recovery after doxycycline treatment. No anti-proliferative effect was observed in vitro, potentially because of the slower in vitro proliferation rate, or because PRKACA might affect differentiation of more stem-like cells.
To our knowledge, BLU0588 and BLU2864 are the first selective small molecule PRKACA enzyme inhibitors. Using these structurally similar molecules, we demonstrate the potential therapeutic value for FLC of inhibiting DNAJB1-PRKACA. In FLC PDX spheroid cultures, BLU0588 recapitulated the effects of DNAJB1-PRKACA knockdown. BLU9058, an additional PRKACA inhibitor which is structurally similar to BLU0588, also inhibited phosphorylated VASP in Tu-2010 FLC spheroids derived from a second FLC PDX model. This suggests that the on-target pharmacology described for BLU0588 and BLU2864 applies in general for DNAJB1-PRKACA driven FLC tumors. In vivo, treatment with BLU0588 and BLU2864 reduced tumor growth by approximately one-half relative to treatment with vehicle 34 days following the start of treatment. This finding was consistent with 3 different shRNA cell line xenografts. The pharmacokinetics of BLU0588 and BLU2864 show that, while 30 mg/kg QD did effectively inhibit downstream signaling of PRKACA, phosphorylated VASP levels returned to baseline levels by 24 hours. BLU0588 and BLU2864 are adenosine-5'-triphosphate (ATP)-competitive inhibitors that inhibit WT PRKACA in addition to the DNAJB1-PRKACA fusion protein. PRKACA is expressed in virtually all tissues and plays a critical role in cardiac function, making a strategy to selectively inhibit DNAJB1-PRKACA while sparing WT PRKACA desirable. The alternative conformation of the holoenzyme containing the DNAJB1-PRKACA fusion protein and the PKA regulatory subunit may constitute a strategy for selectively targeting the activity of the DNAJB1-PRKACA fusion protein 40. In addition, primary and metastatic FLC were shown to be sensitive to clinically available inhibitors of topoisomerase 1 and histone deacetylases, and to napabucasin 41, suggesting these agents as potential therapeutic strategies for FLC. The authors observed a variable
response to PKA inhibitors, which may be due to the lack of sensitivity of the in vitro culture system.

Our findings have identified a gene signature dependent on PRKACA expression, and as such our gene set may contain potentially druggable targets for FLC. Some genes may be directly regulated by PRKACA through phosphorylation of transcription factors, such as HNFα, whereas other genes may be regulated in a more indirect manner. PRKACA regulation of these genes may potentially impact numerous cellular pathways which promote transformation and development of FLC. We observed only a partial overlap in gene expression changes between our findings and the analysis by Simon et al, likely due to using a single in vitro cultured PDX cell line for most assays, whereas the analysis by Simon et al was executed in a larger set of primary tumors and compared to adjacent normal tissue.

Although PRKACA is not a classical oncogene, constitutive activity of PRKACA and PKA signaling is known to play a pathogenic role in human disease and cancer. Activating mutations in PRKACA have been found to underly Cushing’s syndrome in patients with adrenal tumors, and constitutively active PKA signaling has also been shown to drive Carney Complex syndrome. In addition, PRKACA has been shown to mediate chemotherapy resistance. Recent data suggests DNAJB1-PRKACA fusions are not unique to FLC and may also occur in pancreatobiliary neoplasms.

In conclusion, this study supports the hypothesis that FLC tumor growth is dependent upon DNAJB1-PRKACA fusions and serves as an in vivo proof-of-concept that targeting hyperactive PRKACA signaling is a viable therapeutic strategy for patients with FLC. The development of selective PRKACA inhibitors also enables
the validation of PRKACA as a therapeutic target for other diseases as well as for
the study of the cellular function of PRKACA.
Materials and Methods

**Generation of Inducible shRNA Cell Lines**

FLC PDX tumors (Crown Biosciences) were dissociated with 2.5 mg/mL collagenase B (Sigma-Aldrich, #1108807001) in Roswell Park Memorial Institute 1640 medium (Thermo Fisher Scientific, #12633012). Mouse cells were depleted using a Mouse Cell Depletion Kit according to the manufacturer’s protocol (Miltenyi Biotech, #130-104-694). Dissociated FLC PDX cells were cultured as spheroids in Dulbecco’s Modified Eagle Medium (DMEM)/Nutrient Mixture F-12 (Thermo Fisher Scientific, #11330032) containing 20 ng/mL epidermal growth factor (StemCell Technologies, #02633), 10 ng/mL fibroblast growth factor (R&D Systems #233-FB-025), 2% B27 (Thermo Fisher Scientific, #12587010), and 1% N2 (Thermo Fisher Scientific, #17502048) on low-attachment plates. Cells were plated at 100,000 cells/well of 6-well plates (Corning) in culture medium and transduced with $10^6$ viral particles containing PRKACA-targeting or NT shRNA (Horizon Discovery, SMARTvector™ Inducible Human PRKACA shRNA and SMARTvector™ Inducible Non-Targeting Control; PRKACA shRNA V3SH7670 – V3IHSHEG-8406259 [#1], V3IISHEG-6603667 [#2], V3IISHEG-5476684 [#3], V3IHSHEG_8059495 [#4], and NT snRNA VSC6586) in culture medium containing 8 µg/mL polybrene. Clones expressing shRNA constructs were selected for and maintained in 2 µg/mL puromycin.

**Western Blot Analysis**

Frozen tumor sections of FLC PDX tumor tissue were homogenized in PhosphoSafe Extraction Reagent with added Halt™ protease inhibitor cocktail.
Analysis of FLC PDX spheroids expressing inducible PRKACA shRNA, spheroids were treated with 0.5 µg/ml doxycycline or DMSO vehicle for 10 days, or with BLU0588, BLU2864, or DMSO vehicle for 4 hours. Cells were lysed in PhosphoSafe Extraction Reagent (EMD Millipore, #71296) with added Halt™ protease inhibitor cocktail (Thermo Fisher Scientific, #78430). Protein concentration was quantified using the Pierce BCA Protein Assay (Thermo Fisher Scientific, #23227). Proteins were resolved using SDS-PAGE on 20% gradient gels (Bio-Rad, #5671095) and electrotransferred onto nitrocellulose microporous membranes (Bio-Rad, #1704159). Immunodetection was performed using standard procedure and the following primary antibodies (all from Cell Signaling Technology): PRKACA #4782, pVASP #3114, and pCREB (#9198, ROCK #4563, and β-actin loading control #3700). Goat anti-rabbit secondary antibodies were purchased from Invitrogen (#A-21057) and Licor Biosciences (#926-32211), and chemiluminescent signals were detected using the LI-COR Biosciences Odyssey® Imaging System.

As an additional model, BLU9058, a compound structurally similar to BLU0588, was tested in FLC spheroids (PhoenixSongs Biologicals, Donor Lot Tu-2010) previously characterized elsewhere\textsuperscript{30}. Spheroids were cultured in Kubota’s FL-HCC Spheroid Growth Medium (PhoenixSongs Biologicals, Branford, CT, #35002-101) in low attachment flasks. For treatment with BLU9058, FLC Spheroids were dissociated with Papain Dissociation System (Worthington Biochemical Corp., Lakewood, NJ, #LK003150) following the manufacturer’s instructions. Cells were treated with BLU9058 for 4 hours and immunodetection of pVASP and β-actin loading control was performed as described above.
**Quantitative Polymerase Chain Reaction**

Lysates were prepared as described for western blotting. Total RNA was extracted using an RNeasy Plus Mini Kit (Qiagen, #74136) reagent/kit and reverse transcribed to complementary DNA (cDNA) using a High Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific, #4368813). The expression of *PYGL* (assay ID, Hs00958087_m1), *SHH* (assay ID, Hs01123832_m1), *CPS1* (assay ID, Hs00919483_m1), and *G6PC* (assay ID, Hs02560787_s1) was detected using TaqMan™ (FAM) Gene Expression Assays (ThermoFisher Scientific, #4331182) and the TaqMan Gene Expression Master Mix (ThermoFisher Scientific, #4369016), using the ViiA™ 7 Real-Time PCR System (ThermoFisher Scientific, #4453536). The relative quantification of gene expression was calculated using the $2^{-\Delta\Delta Ct}$ method, and gene expression levels were normalized to a housekeeping control (*HMBS*; assay ID, Hs00609296_g1) using ViiA™ 7 software.

**Transcriptome Sequencing**

To evaluate whether FLC gene expression signature depends on pathway activation by *DNAJB1-PRKACA* expression, we assessed gene expression by transcriptome sequencing (RNA sequencing) in the engineered shRNA cell lines. With DESeq2 52 we assessed differential gene expression in PRKACA shRNA cell lines before and after doxycycline induction. Using a false discovery rate threshold of 0.01 and absolute log$_2$ fold change of 1, we detected differentially expressed genes associated with each shPRKACA. A consensus of the differentially expressed genes was defined by overlapping (matching by the log$_2$-fold change direction) significant DESeq2 results for the 3 PRKACA shRNA constructs used.
**Cell Proliferation Analyses**

Dissociated FLC PDX cells were cultured as spheroids, transduced, and selected for expression of shRNA constructs as described above. Cells were plated in 96-well collagen-coated plates. PRKACA shRNA-expressing clones and cells expressing an NT shRNA were treated with 0.5 µg/ml doxycycline (for induction of shRNA) or DMSO vehicle and allowed to grow for 21 days. Proliferation was measured using a CellTiter-Glo® Luminescent Cell Viability Assay (Promega, #G7570) per the manufacturer's instructions.

For determination of the effect of BLU0588 on cell proliferation in vitro, FLC PDX spheroids were cultured as above and were treated with BLU0588 at a range of concentrations, staurosporine, or DMSO vehicle. Proliferation was measured after 14 days as described above.

**Characterization of FLC PDX Tumors in Vivo**

The PDX mouse model of FLC, LI5132 27 (Crown Bioscience) was used, and a control CDX model generated in-house using a Hep3B HCC cell line as a control (Cat #HB-8064, American Type Culture Collection). An FLC PDX model was developed using inducible knockdown shRNA cell lines, which were generated as previously described above.

To humanely co-house animals, experiments were only performed in 6- to 8-week-old female NOD-SCID mice (Jackson Laboratory, Bar Harbor, ME). No differences in pharmacodynamics were anticipated between male and female mice. FLC PDX shRNA cell lines or Hep3B cells were implanted (500,000 cells) subcutaneously into the rear flank. Tumors were allowed to grow to an average size
of 150–250 mm³. For shRNA knockdown experiments, mice were randomized into
doxycycline treatment or control groups using the multi-task method in StudyLog
software (South San Francisco, CA). ShRNA expression was induced using 2 mg/ml
doxycycline and 5% sucrose added to drinking water; control mice received 5%
sucrose in drinking water. Tumors were measured with calipers and mice were
weighed twice weekly. Tumor volume was calculated using the formula volume =
(length × width²)/2.

For immunohistochemical staining in formalin-fixed, paraffin-embedded FLC
PDX tumors, staining was conducted on a Leica Bond RXm (Leica Biosystems)
using standard chromogenic methods. For heat-induced epitope retrieval, slides
were heated in either a pH6 citrate-based buffer for 20 minutes at 96°C (glypican 3,
cytokeratin 7, Ki67), or a pH9 ethylenediaminetetraacetic acid (EDTA)-based buffer
for 20 minutes at 96°C (CD68), followed by a 15-minute antibody incubation.
Antibody binding for Ki67 (Abcam, #ab16667), CD68 (Abcam, #ab955), cytokeratin 7
(Abcam, #ab181598), and glypican 3 (Cell Marque, #261M) was detected using
BOND Polymer Refine Detection (Leica Biosystems, #DS9800), including a
hematoxylin counterstain to visualize nuclei.

**Characterization of BLU0588 and BLU2864**

BLU0588 and BLU2864 were developed from screening hits identified from a
proprietary library of compounds. PRKACA inhibiting activity was screened using the
EZ Reader 2 electrophoretic mobility shift platform (PerkinElmer). PRKACA enzyme
(0.007 ng/mL; Millipore, #539482) or ROCK2 enzyme (0.006 ng/mL; SignalChem,
#R11-11H-10) was added to each well of a 384-well plate containing 1 µM Kemptide
peptide substrate (5-FAM-LRRASLG; AnaSpec 2933), Km concentrations of ATP (5
µM ATP), and a concentration series of test compounds (1% final DMSO) in (100 mM HEPES buffer pH 7.5, 0.015% Brij-35, 10 mM MgCl$_2$, 1 mM DTT) and incubated for 90 minutes at 25°C. The reaction was stopped with addition of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 35 mM EDTA, and 0.2% Coating Reagent 3 [PerkinElmer]). Results were read with the EZ Reader 2 and the IC$_{50}$ was calculated using a 4-parameter fit. For the AKT1-3 Nanosyn enzyme assay, test compounds were diluted in 100% DMSO using 3-fold dilution steps. The final compound concentration in the assay ranged from 10 µM to 0.056 nM, and compounds were tested in a single well for each dilution, with the final concentration of DMSO in all assays kept at 1%. The reference compound, staurosporine, was tested in an identical manner.

Phosphorylation of VASP on Serine 157 was used as a readout of PRKACA cellular activity. Phosphorylation was detected with a homogeneous time-resolved fluorescence assay, following the manufacturer’s protocol (Cisbio, #63ADK066PEH). PKA was activated by the addition of forskolin (Sigma-Aldrich, #F3917), and the dose response to PRKACA inhibitors was measured in forskolin-stimulated human Huh7 cells as follows. Briefly, Huh7 cells were plated at a density of 2 x 10$^4$ cells per well in a 384-well opti-well cell culture plate in 15 µl of serum- and phenol-free DMEM (Gibco, #21063-029), and incubated overnight at 37°C, 5% CO$_2$. The next day, 3 µl of a dosed concentration series of test compound (0.24% DMSO final concentration) was added to the wells, and the cells were incubated for an additional 4 hours at 37°C, 5% CO$_2$. Two µl of forskolin was added at a final concentration of 5 µM and the plates were incubated for 30 minutes at 37°C, 5% CO$_2$. Five µl of lysis buffer containing 1% Halt™ protease cocktail inhibitors (ThermoFisher, #78430), was added to the cells and the mixture was incubated under gentle shaking for 30
min at room temperature. Ten µl of this lysate was transferred to a 384-well proxil
plate and 2.5 µL of the premixed antibody solution was added. An antibody solution
was prepared by combining phospho-VASP cryptate antibody and phospho-VASP
d2 antibody, at 20-fold dilution into a buffer solution following the manufacturer’s
protocol. The lysate and antibody mixture was incubated for either 3 h at room
temperature or overnight at 4°C. The fluorescence emission at 2 different
wavelengths (665 nm and 620 nm) was read on an EnVision instrument.

For in vivo studies of BLU0588 or BLU2864, FLC PDX tumor cells were
implanted subcutaneously into the rear flank of 6- to 8-week-old female NOD-SCID
mice (Jackson Laboratory, Bar Harbor, ME) and allowed to grow to 150 mm³ for
efficacy studies or 500 mm³ for pharmacokinetic/pharmacodynamic studies. Mice
were randomized into control or treatment groups using the multi-task method in
Study Log software. BLU0588 was dissolved in 20% Solutol in 0.5% methylcellulose
and BLU2864 was dissolved in 10% DMSO, 10% Solutol HS15, 20% hydroxypropyl-
cyclodextrin, and administered orally, once daily. Tumor size and mouse body weight
was determined as above. For pharmacokinetic/pharmacodynamic studies, plasma
and tumors were collected at pre-specified time points, and BLU0588 and BLU2864
were detected using Liquid Chromatography Triple Quadrupole Mass Spectrometry.
Phospho-VASP was measured using western blotting as described above.
References

17. Engelholm LH, Riaz A, Serra D, et al. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient


Figures

Figure 1. Characterization of an FLC PDX mouse model.

(A) Expression of DNAJB1-PRKACA protein in extracts from FLC PDX tumors was associated with increased pCREB and pVASP. (B) Hematoxylin and eosin staining of sections from FLC PDX tumors shows a fibrolamellar morphology, and immunohistochemical staining shows positive expression of cytokeratin 7 and CD68, and negative expression of glypican 3 (20X magnification shown).
Figure 2. Effect of DNAJB1-PRKACA knockdown on FLC PDX spheroid cultures in vitro.

(A) Spheroid cultures were generated from FLC PDX tumors (10X magnification shown). (B) Doxycycline treatment leads to DNAJB1-PRKACA and WT PRKACA knockdown in 3 clones expressing doxycycline-inducible shRNA but does not affect DNAJB1-PRKACA levels in cells expressing a non-targeting shRNA (3 independent biological experiments). (C) Doxycycline treatment does not affect proliferation of PRKACA shRNA-expressing clones or of cells expressing a non-targeting shRNA. Graph Bars and error bars represent the mean ± SD (7 technical replicates and 2 biological replicates). (D) Addition of forskolin (10 µM) increases pCREB and pVASP in extracts from Huh7 HCC cells and has no effect on pCREB or pVASP in extracts from FLC PDX tumors (2 independent biological replicates conducted on different days).
Figure 3. Effect of DNAJB1-PRKACA knockdown on PDX tumor growth in vivo.

(A–C), Reduction in the growth rate of PDX tumors expressing doxycycline-inducible PRKACA shRNA was evident in mice treated with doxycycline compared with those that were not. Dots and error bars represent the mean ± SEM ([A] 6 animals per group; [B] 8 animals per group and the study was run twice with comparable results; [C] 6 animals in control group and 7 animals in doxycycline group). (D) No change in the growth rate of PDX tumors expressing doxycycline-inducible non-targeting shRNA was evident in mice treated with doxycycline compared with those that were not. Dots and error bars represent the mean ± SEM (6 animals per group and study was run twice with comparable results). (E) Expression of DNAJB1-PRKACA fusion protein, but not WT PRKACA, was reduced in vivo using shRNA #1 at 10 and 20 days. Non-targeting (NT) shRNA had no effect on fusion protein or WT protein expression (western blot of cell lysate n = 1; lysate from 3 animals per condition). (F) Measurement of DNAJB1-PRKACA and WT PRKACA expression in extracts from FLC PDX tumors expressing clone #2 indicated DNAJB1-PRKACA expression recovers by 28 days after doxycycline treatment of mice (3 animals per condition for shRNA induction; 3 independent western blots of tumor lysate). (G) Immunohistochemical staining (4X magnification shown) shows the reduction in Ki67-positive nuclei in FLC PDX tumors within 10 days following doxycycline induction, and recovery to baseline levels approximately 28 days after doxycycline induction. Tumors from 3 mice per group were processed and stained for Ki67. (H) Ki67 percentage positive. Bar graphs and error represent mean ± SEM (3 xenograft tumors per group).
Figure 4. Effect of BLU0588 and BLU2864 on FLC PDX cells in vitro and on FLC PDX growth in vitro.

(A) Structure of BLU0588 and BLU2864. (B) Treatment of FLC PDX cells with BLU0588 reduced pVASP in a dose-dependent manner. Experiment was independently repeated 3 times. (C) BLU0588 did not affect FLC PDX cell proliferation after 14 days compared with staurosporine treatment. Squares/dots and error bars represent mean ± SEM (1 biological replicate and 6 technical replicates). (D) The plasma concentration of BLU0588 and BLU2864 (right axis, dots) is shown with the level of pVASP (left axis, bars) after treatment with 30 mg/kg QD and 45 mg/kg QD (BLU2864) or 75 mg/kg QD (BLU0588) orally. Graph bars/dots and error bars represent mean ± SEM (PKPD analysis was conducted once with 3 animals per group [BLU0588] and twice with 3 animals per group [BLU864]). (E) Mouse body weight over time after treatment with 30 mg/kg QD BLU0588 and BLU2864. Dots and error bars represent mean ± SEM (study was conducted once with 9 animals per group [BLU0588] and once with 8 animals per group [BLU2864]). (F) Growth of FLC PDX tumors was reduced in mice treated with 30 mg/kg QD BLU0588 and BLU2864 compared with those treated with vehicle. Dots and error bars represent mean ± (study was conducted once with 9 animals per group [BLU0588] and once with 8 animals per group [BLU2864]).
Figure 5. Identification of FLC-specific genes affected by PRKACA Inhibition.

(A) Overlap of consensus shRNA with BLU0588 modulated gene expression. (B) Overlap of PRKACA inhibition signature with FLC gene signature.
Figure 6. Effect of PRKACA knockdown or inhibition on FLC-specific gene expression.

(A) Doxycycline reversed an FLC-specific gene signature, leading to downregulation of genes that are overexpressed in FLC (CPS1 and G6PC, top) and upregulation of genes that are underexpressed in FLC (PYGL and SHH, bottom). Graph bars and error bars represent the mean ± SD (5 technical replicates and 3 independent biological replicates conducted on 3 different days). (B) BLU0588 treatment (1.5 µM for 1 day or 14 days) reversed a FLC-specific gene signature, leading to downregulation of genes that are overexpressed in FLC (CPS1 and G6PC, top) and upregulation of genes that are underexpressed in FLC (PYGL and SHH, bottom; 5 technical replicates and 2 independent biological replicates).
Supplementary information

Supplementary Table S1. Characterization of BLU0588 and BLU2864
See attached excel file Schalm et al Supplemental Tables, tab “Table S1”

Supplementary Table S2. Binding Profile of BLU0588 and BLU2864
See attached excel file, tab “Table S2”

Supplementary Table S3. Percent PRKACA Fusion Reads
See attached excel file, tab “Table S3”

Supplementary Table S4. Consensus PRKACA shRNA Modulated Genes
See attached Excel file, tabs “Table S4A and S4B”

Supplementary Table S5. Genes Modulated by BLU0588 vs DMSO
See attached Excel file, tabs “Table S5A and S5B”

Supplementary Table S6. Genes Modulated by BLU0588, Compared With FLC-Related Genes in the Simon et al Dataset
See attached Excel file, tabs “Table S6A and S6B”

Supplementary Table S7. Genes Modulated by Both BLU0588 Treatment and shRNA Knockdown, and With Inverse Modulation in FLC
See attached Excel file, tabs “Table S7A and S7B”
Supplementary Figure S1. (A) **DNAJB1-PRKACA** gene fusion. (B) **DNAJB1-PRKACA** fusion results in upregulation of **PRKACA** expression.
Supplementary Figure S2. (A–B) BLU0588 dose-dependently decreases VASP phosphorylation in FCL PDX spheroid cultures (3 biological replicates).

(A) pVASP inhibition in FLC

(B) BLU0588 (nM) vs pVASP and Actin
Supplementary Figure S3. Effect of BLU9058 on LI5132 and Tu-2010 PRKACA signaling.

A  
BLU9058 structure

B  
LI5132 FLC PDX cell line  
Tu-2010 FLC PDX cell line

<table>
<thead>
<tr>
<th>BLU9058 (μM)</th>
<th>10</th>
<th>5</th>
<th>2.5</th>
<th>1.25</th>
<th>0.6</th>
<th>0.3</th>
<th>0.15</th>
<th>0.08</th>
<th>0.04</th>
<th>0.02</th>
<th>0.01</th>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>pVASP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Supplementary Figure S4. PRKACA transcript level reads by shRNA in FLC cell lines.

Wilcoxon rank test $P = 0.022$ for all doxycycline vs no doxycycline.
Supplementary Figure S5. Overlap of consensus between PRKACA shRNA and published FLC gene signature\textsuperscript{14}.

No significant category found

51 genes

Differential expressed genes
FLC vs normal
Positive FC

Differential expressed genes
PRKACA shRNA vs NT shRNA
Negative FC

1407 genes
Simon et al 2015
FLC vs normal

242 genes

2031 genes

330 genes

Differential expressed genes
FLC vs normal
Negative FC

Differential expressed genes
PRKACA shRNA vs NT shRNA
Positive FC

39 genes

FDR ≤ 0.01 and
\( \log_2(FC) ≥ 1 \)

- EPITHELIAL_MESENCHYMAL_TRANSITION
- ESTROGEN_RESPONSE_LATE
- COAGULATION
- TNFA_SIGNALING_VIA_NFKB
- CHOLESTEROL_HOMEOSTASIS
- IL6_JAK_STAT3_SIGNALING
Supplementary Figure S6. (A) Overlap of consensus shRNA with BLU0588 modulated gene expression. (B) Overlap of PRKACA inhibition signature with FLC gene signature.
Supplementary Figure S7. Transcription factor binding and network analysis.

(A) Transcription factor motifs enriched in genes modulated by BLU0588, PRKACA shRNA knockdown, and the combined signature of PRKACA inhibition. (B) Clarivate Metacore analysis established networks connecting the differentially expressed genes and associated transcription factor motifs.
Supplementary Figure S8. BLU0588 dose-dependently reduces expression of genes normally upregulated in FLC (A) and dose-dependently increases expression of genes that are normally downregulated in FLC (B).
<table>
<thead>
<tr>
<th></th>
<th>LI5132 FLC PDX tumor</th>
<th>Hep3B CDX tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNAJB1-PRKACA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT PRKACA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pCREB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pVASP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**H&E stain:** epithelial histology

- **Cytokeratin 7 (IHC):** positive
- **CD68 (IHC):** positive
- **Glypican 3 (IHC):** negative
A FLC PDX spheroid

B

<table>
<thead>
<tr>
<th>shRNA</th>
<th>NT</th>
<th>#1</th>
<th>#2</th>
<th>#3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxycycline</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>DNAJB1-PRKACA</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>PRKACA WT</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>pVASP</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>Actin</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
</tbody>
</table>

C

21-day proliferation

- Vehicle
- Doxycycline

D

Forskolin

<table>
<thead>
<tr>
<th>Serum</th>
<th>Huh7 cells</th>
<th>FLC PDX tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>+</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>+</td>
<td>–</td>
<td>+</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>pCREB</th>
<th>pVASP</th>
<th>Actin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**A**

- **shRNA #1**
  - TGI = 73% (Day 23)
  - \( P = 0.003 \)

- **Control**
  - **Doxycycline**

- **shRNA #2**
  - TGI = 78% (Day 22)
  - \( P < 0.0001 \)

**C**

- **shRNA #4**
  - TGI = 77% (Day 22)
  - \( P = 0.02 \)

**E**

- **shRNA #1**
  - **Doxycycline**
  - **DNAJB1-PRKACA**
  - **PRKACA WT**
  - **Actin**

- **NT shRNA**

**F**

- **shRNA #2**
  - **DNAJB1-PRKACA**
  - **PRKACA WT**
  - **Actin**

**G**

- **No Dox**
  - 10 days
  - 20 days
  - 28 days
  - 43 days

- **+ Dox**

**H**

- **Ki67 positive (%)**
  - **Time after induction (days)**
  - No Dox
  - + Dox
A

Differential expressed genes
BLU0588 vs DMSO
Negative FC

323 genes

BLU0588 vs DMSO

494 genes

Differential expressed genes
BLU0588 vs DMSO
Positive FC

88 genes

Differential expressed genes
PRKACA shRNA vs NT shRNA
Negative FC

242 genes

PRKACA shRNA vs NT shRNA

330 genes

No significant category found

Common differentially expressed genes under PRKACA inhibition

26 genes

FDR ≤ 0.01 and log₂ (FC) ≥ 1

B

Differential expressed genes
FLC vs normal
Positive FC

1407 genes

Simon et al 2015
FLC vs normal

2031 genes

Differential Expressed genes
FLC vs normal
Negative FC

88 genes

Signature of PRKACA inhibition (BLU0588 and shRNA)

188 genes

Common differentially expressed genes under PRKACA inhibition

13 genes

No significant category found

FDR ≤ 0.01 and log₂ (FC) ≥ 1